Search

Your search keyword '"Ehrencrona, Hans"' showing total 574 results

Search Constraints

Start Over You searched for: Author "Ehrencrona, Hans" Remove constraint Author: "Ehrencrona, Hans"
574 results on '"Ehrencrona, Hans"'

Search Results

3. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

9. Implementing precision medicine in a regionally organized healthcare system in Sweden

10. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.

13. Genetic counselling legislation and practice in cancer in EU Member States

14. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia : Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

15. Genetic counselling legislation and practice in cancer in EU Member States.

16. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

17. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

18. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.

19. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients

20. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

21. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.

22. Clinical and genetic analyses of a Swedish patient series diagnosed with ataxia

23. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study

26. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers

27. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.

28. S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL

29. S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY

32. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility

34. Supplementary Table 2 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

35. Supplementary Tables 1-4 from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

36. Supplementary Table 3 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

37. Data from Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

38. Abstract P6-02-15: Don’t get lost in translation: Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) recommendations for reporting germline cancer susceptibility gene variants in 19 languages – breast cancer as a model

39. Building a precision medicine infrastructure at a national level: The Swedish experience

41. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

43. Additional file 3 of Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study

45. Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany

46. The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

48. Extended genetic diagnostics for children with profound sensorineural hearing loss by implementing massive parallel sequencing. Diagnostic outcome, family experience and clinical implementation

49. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

Catalog

Books, media, physical & digital resources